Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Agents targeting inflammation in heart failure.

Lars Gullestad1, John Kjekshus, Jan Kristian Damås

  • 1Department of Cardiology, University of Oslo, N-0027 Oslo, Norway. lars.gullestad@medisin.uio.no

Expert Opinion on Investigational Drugs
|June 2, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In-depth analysis of sampling practice and yield of blood cultures.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2026
Same author

Impact of tofacitinib on growth in patients with juvenile idiopathic arthritis.

Annals of the rheumatic diseases·2026
Same author

Long-term trends in incidence and mortality in Staphylococcus aureus bacteraemia; a retrospective population-based study from Central Norway 1996-2022.

BMC infectious diseases·2026
Same author

Risk of serious infections, myocardial infarction or stroke, venous thromboembolic events, and malignancy in patients with psoriatic arthritis treated with tofacitinib compared with biologic treatments in the United States.

Arthritis research & therapy·2026
Same author

Patients' Perspectives Regarding Ankylosing Spondylitis Treatment Administration Features: Evidence from Qualitative Interviews and a Multinational Quantitative Preference Survey.

Rheumatology and therapy·2026
Same author

Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease.

Annals of the rheumatic diseases·2025

Inflammation plays a key role in chronic heart failure (HF) pathogenesis, causing an inflammatory imbalance. While anti-TNF therapies show no effect, other immunomodulating treatments offer promise for future HF management.

Area of Science:

  • Cardiology
  • Immunology
  • Pathophysiology

Background:

  • Inflammatory mediators are implicated in chronic heart failure (HF) pathogenesis.
  • Elevated pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) are observed in HF patients.
  • An inflammatory imbalance exists due to a lack of corresponding increase in anti-inflammatory cytokines (IL-10, TGF-beta).

Purpose of the Study:

  • To explore the role of inflammatory mediators in chronic heart failure.
  • To evaluate the effectiveness of current and potential therapeutic strategies targeting inflammation in HF.

Main Methods:

  • Review of experimental and clinical trial evidence.
  • Analysis of cytokine levels in HF patients (plasma, leukocytes, myocardium).
  • Assessment of outcomes from randomized, placebo-controlled anti-TNF studies and smaller immunomodulating treatment studies.

Related Experiment Videos

Main Results:

  • Traditional cardiovascular drugs have minimal impact on the HF cytokine network.
  • Randomized anti-TNF studies showed a lack of therapeutic effect.
  • Smaller studies suggest potential benefits from pentoxifylline, IV immunoglobulin, thalidomide, and statins.

Conclusions:

  • The 'cytokine hypothesis' in HF remains plausible despite negative anti-TNF trial results.
  • Developing effective HF treatments requires a deeper understanding of the complex cytokine network.
  • Further research is needed to identify key players in HF immunopathogenesis and confirm promising immunomodulatory treatments.